Gilmore Neil O'Neill sold $16k of EDIT
CEO at Editas Medicine, Inc.. 5,124 shares at an average of $3.04, traded Sep 3, 2026, filed Sep 4, 2026.
Score components
- +25RoleCEO
- 0Trade size$16k at market
- 0Share of holdings soldSold 2.1% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001742084-26-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | SOpen-market sale Common Stock10b5-1 | -5,124 | $3.04 | $16k | 243,189 | 38 d ago |
Related signals
Other insiders at Editas Medicine, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | Editas Medicine, Inc. | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | $2,153 709 shares | -1% | |
| 17Weak | Editas Medicine, Inc. | Amy Parison SVP, Chief Financial Officer | $1,376 453 shares | -3% | |
| 10Weak | Editas Medicine, Inc. | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | $1,843 710 shares | -1% | |
| 20Weak | Editas Medicine, Inc. | Gilmore Neil O'Neill CEO | $15k 5,592 shares | -2% | |
| 17Weak | Editas Medicine, Inc. | Amy Parison SVP, Chief Financial Officer | $1,189 458 shares | -3% | |
| 10Weak | Editas Medicine, Inc. | Amy Parison SVP, Chief Financial Officer | $1,752 679 shares | -4% | |
| 3Weak | Editas Medicine, Inc. | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | $13k 5,121 shares | -7% | |
| 10Weak | Editas Medicine, Inc. | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | $1,252 726 shares | -1% | |
| 25Weak | Editas Medicine, Inc. | Gilmore Neil O'Neill CEO | $26k 15,192 shares | -5% | |
| 17Weak | Editas Medicine, Inc. | Amy Parison SVP, Chief Financial Officer | $769 446 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.